Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 23104350)

1.

Identification of T cell epitopes of Mycobacterium tuberculosis with biolistic DNA vaccination.

Nagata T, Koide Y.

Methods Mol Biol. 2013;940:285-303. doi: 10.1007/978-1-62703-110-3_22.

PMID:
23104350
2.

Mycobacterium tuberculosis virulence: insights and impact on vaccine development.

Delogu G, Provvedi R, Sali M, Manganelli R.

Future Microbiol. 2015 Jun 29:1-18. [Epub ahead of print]

PMID:
26119086
3.

Identification of Novel Potential Vaccine Candidates against Tuberculosis Based on Reverse Vaccinology.

Monterrubio-López GP, González-Y-Merchand JA, Ribas-Aparicio RM.

Biomed Res Int. 2015;2015:483150. doi: 10.1155/2015/483150. Epub 2015 Apr 15.

4.

Developing aerosol vaccines for Mycobacterium tuberculosis: Workshop proceedings: National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, April 9, 2014.

Aerosol Vaccines for Tuberculosis Workshop Summary Group.

Vaccine. 2015 Jun 12;33(26):3038-46. doi: 10.1016/j.vaccine.2015.03.060. Epub 2015 Apr 11.

5.

Developing vaccines to prevent sustained infection with Mycobacterium tuberculosis: Conference proceedings: National Institute of Allergy and Infectious Diseases, Rockville, Maryland USA, November 7, 2014.

Vaccine Prevention of Sustained Mycobacterium tuberculosis Infection Summary Group.

Vaccine. 2015 Jun 12;33(26):3056-64. doi: 10.1016/j.vaccine.2015.03.061. Epub 2015 Apr 11.

6.

B cells and antibodies in the defense against Mycobacterium tuberculosis infection.

Achkar JM, Chan J, Casadevall A.

Immunol Rev. 2015 Mar;264(1):167-81. doi: 10.1111/imr.12276.

PMID:
25703559
7.

The onset of adaptive immunity in the mouse model of tuberculosis and the factors that compromise its expression.

Robinson RT, Orme IM, Cooper AM.

Immunol Rev. 2015 Mar;264(1):46-59. doi: 10.1111/imr.12259.

PMID:
25703551
8.

A PE_PGRS33 protein of Mycobacterium tuberculosis: an ideal target for future tuberculosis vaccine design.

Gastelum-Aviña P, Velazquez C, Espitia C, Lares-Villa F, Garibay-Escobar A.

Expert Rev Vaccines. 2015 May;14(5):699-711. doi: 10.1586/14760584.2015.1015995. Epub 2015 Feb 19.

PMID:
25693607
9.

An overview of tuberculosis plant-derived vaccines.

Rosales-Mendoza S, Ríos-Huerta R, Angulo C.

Expert Rev Vaccines. 2015 Jun;14(6):877-89. doi: 10.1586/14760584.2015.1015996. Epub 2015 Feb 16.

PMID:
25683476
10.

TB Vaccines: The (Human) Challenge Ahead.

Hokey DA.

Mycobact Dis. 2014 Aug;4(4):e128. No abstract available.

11.

The present and future of tuberculosis vaccinations.

Principi N, Esposito S.

Tuberculosis (Edinb). 2015 Jan;95(1):6-13. doi: 10.1016/j.tube.2014.10.004. Epub 2014 Oct 22.

PMID:
25458613
12.

Understanding and overcoming the barriers to T cell-mediated immunity against tuberculosis.

Urdahl KB.

Semin Immunol. 2014 Dec;26(6):578-87. doi: 10.1016/j.smim.2014.10.003. Epub 2014 Oct 28. Review.

PMID:
25453230
13.

Significance of antigen and epitope specificity in tuberculosis.

Ivanyi J, Ottenhoff TH.

Front Immunol. 2014 Oct 23;5:524. doi: 10.3389/fimmu.2014.00524. eCollection 2014. No abstract available.

14.

Structural integrity of the antigen is a determinant for the induction of T-helper type-1 immunity in mice by gene gun vaccines against E. coli beta-galactosidase.

Deressa T, Stoecklinger A, Wallner M, Himly M, Kofler S, Hainz K, Brandstetter H, Thalhamer J, Hammerl P.

PLoS One. 2014 Jul 15;9(7):e102280. doi: 10.1371/journal.pone.0102280. eCollection 2014.

15.

Innovative Strategies to Identify M. tuberculosis Antigens and Epitopes Using Genome-Wide Analyses.

Geluk A, van Meijgaarden KE, Joosten SA, Commandeur S, Ottenhoff TH.

Front Immunol. 2014 Jun 25;5:256. doi: 10.3389/fimmu.2014.00256. eCollection 2014. Review.

16.

Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosis.

Yuk JM, Jo EK.

Clin Exp Vaccine Res. 2014 Jul;3(2):155-67. doi: 10.7774/cevr.2014.3.2.155. Epub 2014 Jun 20. Review.

17.

Antigens for CD4 and CD8 T cells in tuberculosis.

Lindestam Arlehamn CS, Lewinsohn D, Sette A, Lewinsohn D.

Cold Spring Harb Perspect Med. 2014 May 22;4(7):a018465. doi: 10.1101/cshperspect.a018465. Review.

PMID:
24852051
18.

Role of Fused Mycobacterium tuberculosis Immunogens and Adjuvants in Modern Tuberculosis Vaccines.

Junqueira-Kipnis AP, Marques Neto LM, Kipnis A.

Front Immunol. 2014 Apr 23;5:188. doi: 10.3389/fimmu.2014.00188. eCollection 2014. Review.

19.

Using humans to make a human leishmaniasis vaccine.

Kamhawi S, Oliveira F, Valenzuela JG.

Sci Transl Med. 2014 Apr 30;6(234):234fs18. doi: 10.1126/scitranslmed.3009118.

PMID:
24786322
20.

Strategies for improving DNA vaccine performance.

Iurescia S, Fioretti D, Rinaldi M.

Methods Mol Biol. 2014;1143:21-31. doi: 10.1007/978-1-4939-0410-5_3.

PMID:
24715280
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk